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Molecular analyses have led to an improvement of the
prognostic evaluation of patients with acute myeloid
leukemia (AML). The European LeukemiaNet (ELN) has pub-
lished a classification that identifies prognostic subgroups
based on the patients’ cytogenetic and molecular genetic
characteristics. At present, therapy decisions are guided by
pre-therapeutic risk assessments.1 Nevertheless, there are still
patients who suffer from relapse despite belonging to the
favorable risk group2,3 and more individualized therapy regi-
mens are needed to prevent relapses. 
Monitoring minimal residual disease (MRD) could become
an important way to identify patients at high risk of relapse.4
In patients with acute lymphoblastic leukemia or chronic
myeloid leukemia, the MRD status routinely guides therapy
decisions at different check points.5,6 Patients with acute lym-
phoblastic leukemia in complete remission after treatment
within the GMALL protocol and with a MRD level of >10-4
at week 16 should undergo hematopoietic allogeneic stem
cell transplantation (HSCT). Pre-emptive arsenic trioxide
therapy in patients with acute promyelocytic leukemia with
t(15;17)(q22;q12) PML-RARA, initiated on the basis of
increasing MRD levels, was seen to prevent relapses in the
MRC 15 trial.7
AML has a wide spectrum of molecular markers.1 Some of
these markers can be assessed by quantitative real-time poly-
merase chain reaction (RT-PCR), e.g. leukemia-specific
fusion transcripts, mutated genes, or aberrantly expressed
genes. These molecular markers can be monitored with high-
er sensitivity by RT-PCR than by other methods such as
immunophenotyping.4,8
MRD assessments after induction and consolidation thera-
py showed a significant impact on relapse-free and overall
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Monitoring minimal residual disease is an important way to identify patients with acute myeloid leukemia at
high risk of relapse. In this study we investigated the prognostic potential of minimal residual disease monitoring
by quantitative real-time polymerase chain reaction analysis of NPM1 mutations in patients treated in the
AMLCG 1999, 2004 and 2008 trials. Minimal residual disease was monitored - in aplasia, after induction therapy,
after consolidation therapy, and during follow-up - in 588 samples from 158 patients positive for NPM1 muta-
tions A, B and D (with a sensitivity of 10-6). One hundred and twenty-seven patients (80.4%) achieved complete
remission after induction therapy and, of these, 56 patients (44.1%) relapsed. At each checkpoint, minimal resid-
ual disease cut-offs were calculated. After induction therapy a cut-off NPM1 mutation ratio of 0.01 was associ-
ated with a high hazard ratio of 4.26 and the highest sensitivity of 76% for the prediction of relapse. This was
reflected in a cumulative incidence of relapse after 2 years of 77.8% for patients with ratios above the cut-off ver-
sus 26.4% for those with ratios below the cut-off. In the favorable subgroup according to European LeukemiaNet,
the cut-off after induction therapy also separated the cohort into two prognostic groups with a cumulative inci-
dence of relapse of 76% versus 6% after 2 years. Our data demonstrate that in addition to pre-therapeutic factors,
the course of minimal residual disease in an individual is an important prognostic factor and could be included in
clinical trials for the guidance of post-remission therapy. The trials from which data were obtained were regis-
tered at www.clinicaltrials.gov (#NCT01382147, #NCT00266136) and at the European Leukemia Trial Registry
(#LN_AMLINT2004_230). 
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ABSTRACT
survival and serial MRD assessments throughout the fur-
ther follow-up could predict impending relapse.9-12 One of
the established MRD markers in AML is the mutated
Nucleophosmin 1 gene (NPM1). In approximately 30% of
all AML patients NPM1 is mutated with the main point
mutations A, B, and D which occur in 95% of all NPM1-
mutated patients.13,14 Depending on an additional fms-like
tyrosine kinase receptor 3 internal tandem duplication
(FLT3-ITD) the general prognosis of patients with NPM1
mutations is favorable.1,15 NPM1 mutations are reliable
markers for monitoring MRD after conventional
chemotherapy, allogeneic HSCT, or during the subse-
quent follow-up.10,11,16,17 There has been some discussion
on the stability of this MRD marker in relapse, but NPM1
mutations could be detected in at least 91% of all relapsed
patients.10,18
In this study, we analyzed MRD monitoring by RT-PCR
in 158 adult patients with NPM1 A, B and D mutations
treated with high-dose cytarabine induction therapies
within the AMLCG 1999, 2004 and 2008 trials. We estab-
lished clinically useful cut-offs at different time points and
showed the impact of MRD levels, in terms of NPM1
mutation ratios, on clinical outcome.  
Methods
Patients
Since 2005 all AML patients have been routinely retrospec-
tively and prospectively screened for NPM1 mutations by melt-
ing curve-based LightCycler assay19 at the Laboratory for
Leukemia Diagnostics of the Department of Internal Medicine
III, University of Munich, Grosshadern. Patients screened posi-
tive for NPM1 mutations (NPM1mut) and with at least one RT-
PCR result after the initial diagnosis were included in this retro-
spective study. All patients were enrolled into one of the follow-
ing AMLCG trials: AMLCG 1999 (n=91),20 AMLCG 2004
(n=29),21 and AMLCG 2008 (n=38, NCT01382147) and gave
written informed consent to treatment and genetic analyses
according to the Declaration of Helsinki. All trials were
approved by the relevant institutional review boards and ethics
committees of the participating institutions.
Treatment, sampling and minimal residual disease
monitoring
Younger patients, i.e. those under the age of 60, received
either sequential high-dose cytarabine with mitoxantrone
(sHAM21), or double induction with standard-dose cytarabine,
daunorubicin and thioguanine followed by high-dose cytarabine
with mitoxantrone (TAD-HAM), or two courses of high-dose
cytarabine with mitoxantrone (HAM-HAM20). In older patients,
over the age of 60, induction therapy consisted of either reduced
dose sHAM21 or one to two courses of intermediate-dose cytara-
bine with mitoxantrone (HAM-HAM20,21). Post-induction thera-
py consisted of TAD consolidation (with subsequent mainte-
nance therapy according to the AMLCG standard20,22) and/or
HSCT. MRD was monitorined by RT-PCR in 588 bone marrow
samples from 158 patients. It was recommended that bone mar-
row was collected and MRD analyzed at diagnosis, during apla-
sia within induction therapy, after induction therapy, after con-
solidation therapy, and every 3 months during the maintenance
therapy or after completion of the therapy (Table 1, Online
Supplementary Figure S1).
Quantitative assessment of NPM1 mutations A, B, and D
Sample preparation and the conditions of the RT-PCR assay of
NPM1mut A were as described by Papadaki et al.18 The primers
and probes used for NPM1mut B and D were those published by
Gorello et al.,16 while the RT-PCR assay conditions and analyses
for these mutations were analogous to those described by
Papadaki et al.with a maximum sensitivity of 10-6 in a serial dilu-
tion of a NPM1mut-negative cell line. MRD levels of the samples
were expressed as a ratio of the NPM1mut normalized to the
housekeeping gene ABL1 and divided by the NPM1mut/ABL1
ratio of an internal calibrator (the OCI/AML3 cell line). 
Clinical endpoints and statistical analyses
The definitions of the clinical endpoints (relapse-free survival
and overall survival) and remission criteria follow the
International Working Group guidelines.23 Survival data were
censored at the time of HSCT for those patients in whom HSCT
was performed in first complete remission. Cut-off values in
aplasia, after induction therapy and after consolidation therapy
of the absolute NPM1mut ratios and of their kinetics (log differ-
ence to NPM1mut ratio at diagnosis) were determined by Cox
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Table 1. Sampling and median NPM1mut ratios of 158 patients at different MRD checkpoints.
At In After After During At
diagnosis aplasia induction consolidation maintenance/ relapse
therapy therapy follow-up
Samples (n) 138 64 106 71 164 (of 49 pts) 45
All patients
Median NPM1mut ratio 73.2 1.4 0.008 0.0003 0.000001 58.8
(range) 0.3 -947 0.000001 – 1010.0 0.000001 – 55.3 0.000001 – 126.0 0.000001 – 115.0 0.000001 – 326.0
Median NPM1mut kinetics* -- - 1.7 - 3.7 - 4.8 -- --
(range) - 8.1 – 0.2 - 8.4 – 0.4 - 8.4 – 0.5
Patients in complete remission after induction therapy
Median NPM1mut ratio 71.6 1.6 0.009 0.000001 0.000001 --
(range) 0.3 -947 0.02 - 1010.0 0.000001 – 55.3 0.000001 – 58.5 0.000001 – 115.0
Median NPM1mut kinetics* -- - 1.6 - 3.7 - 5.5 -- --
(range) - 4.2 – 0.2 - 8.4 – 0.4 - 8.4 – 0.2
pts: patients; NPM1mut: NPM1 mutation; *Log reduction in relation to the sample at diagnosis.
proportional hazards regression models with respect to the high-
est hazard ratios and the lowest P values. For the prediction of
relapse within an observation period of 100 days during the fol-
low-up, we considered the absolute values before relapse for the
patients who did replapse or the peak value of measurements for
patients who did not relapse during the follow-up. With the help
of receiver-operating characteristics (ROC) curve analysis we
selected a cut-off for the prediction of relapse within 100 days in
the follow-up period. The Kaplan-Meier estimator and log-rank
test were used to calculate survival data. The cumulative inci-
dence of relapse was calculated according to Gray.24
All analyses were performed using the SPSS 21 Windows soft-
ware package (IBM, Armonk, NY, USA), or the software envi-




The whole study population consisted of 158 AML
patients (median age 57 years, range 18 – 80) with
NPM1mut A, B or D. Of these 158 patients, 127 patients
achieved a complete remission (80.4%) and 16 an incom-
plete complete remission (10.1%) after induction therapy.
Eight patients (5.1%) had refractory disease, two patients
(1.3%) died during induction therapy, and in five patients
(3.2%) no remission status was available. HSCT was per-
formed in first complete remission in 30 patients (19%).
After a median follow-up of 18.6 months (range, 0.8 –
108.9 months), 56 patients in complete remission had a
relapse (44.1%) and 48 patients (30.4%) died. Further
characteristics are summarized in Table 2. 
NPM1 mutation ratios at different time points
NPM1 mutation ratios at diagnosis
NPM1mut ratios were determined by RT-PCR at diag-
nosis in 138 bone marrow samples. NPM1mut ratios
(median ratio 73.2; range, 0.3 – 947.9, Online
Supplementary Figure S2) did not affect the cumulative
incidence of relapse (P=0.59), overall survival (P=0.69), or
complete remission rate after induction therapy (P=0.78).
NPM1mut ratios at diagnosis showed no correlation or
association with FLT3-ITD mutation status (P=0.54), ELN
risk stratification1 (P= 0.86), blast count (P=0.82), white
blood cell count (P=0.76), or lactate dehydrogenase level
(P= 0.64).
NPM1 mutation ratios at the time of aplasia during induction
therapy
Bone marrow samples from 64 patients in aplasia (day
16 – 18 after the initiation of induction therapy), regard-
less of the response to induction therapy, were available
for analysis. The median bone marrow blast count of all
patients during aplasia was 0% (range, 0 – 96%). Patients
with refractory disease after induction therapy had a
higher blast count in aplasia than patients in complete
remission after induction therapy (median 7.5% versus
0%, P=0.03). Bone marrow blast count did not show any
impact on cumulative incidence of relapse or overall sur-
vival in complete remission patients after induction ther-
apy. Interestingly, neither the absolute NPM1mut ratios
nor the NPM1mut kinetics were significantly different
between patients who achieved complete remission and
patients who did not. 
For subsequent analyses only patients who achieved
complete remission after induction therapy were analyzed
(n=49). At this early stage of treatment all patients still
showed detectable RT-PCR signals (Figure 1, Table 1).
Patients who stayed in remission showed a trend to having
lower NPM1mut ratios and greater NPM1mut log reduc-
tion kinetics than those in patients who had a relapse
(median NPM1mut ratio 1.00 versus 2.4, P=0.077, and
median NPM1mut ratio reduction of -1.6 log versus -1.4 log,
P=0.074; Figure 1). To determine the prognostic value of
MRD monitoring in complete remission patients, we ana-
lyzed Cox regression models. The NPM1mut kinetics but
not the absolute levels were significant prognostic indica-
tors for the occurrence of relapse. Clinical cut-offs were
determined by Cox proportional hazards regression. A
cut-off ratio of 10 for the absolute NPM1mut ratios and a
cut-off of -1 log for the kinetics resulted in sensitivities of
29% and 39%, respectively, and specificities of 96%
(Table 3). Both cut-offs showed a significant prognostic
impact on remission duration [hazard ratio (HR) 2.81,
P=0.034, and HR 4.55, P=0.002, respectively] and on
cumulative incidence of relapse (Online Supplementary
Figure 3A,B). Overall survival was not significantly influ-
enced by MRD levels at this checkpoint (Table 4, Online
Supplementary Figure 3C,D). In addition, multivariate
analyses revealed that MRD cut-offs at aplasia were sig-
nificant independent predictors for relapse if combined
with the ELN risk stratification (Table 4).
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Table 2. Demographics and clinical characteristics of the 158
patients.
N. %





Normal karyotype 139/154 90
Deletion 9q 3/154 2
Trisomy 4 2/154 1












Intermediate – I 61/154 40
Intermediate – II 11/154 7
Adverse 4/154 3
HSCT in first complete remission 30 19
Median follow-up in months (range) 19 (1-109)
Median WBC x109 /L at diagnosis (range) 22 (1-406)
Median LDH in U/L at diagnosis (range) 487 (108-14332)
ITD: internal tandem duplication; TKD: tyrosine kinase domain; ELN: European
LeukemiaNet; HSCT: allogeneic hematopoietic stem cell transplantation; WBC: white
blood cell count; LDH: lactate dehydrogenase; *According to Döhner et al.1
NPM1 mutation ratios after induction therapy
Bone marrow samples from 91 patients in complete
remission after induction therapy were available for
analysis. Absolute NPM1mut ratios and their kinetics
(Table 1) after induction therapy had a significant prog-
nostic impact on the occurrence of relapse (Table 3).
Patients with ongoing remission had significantly lower
NPM1mut ratios and greater log reductions than patients
with relapse during follow-up (median NPM1mut ratio of
0.004 versus 0.11, P=0.001 and median log reduction of -4.4
versus -3.0 log, P=0.001; Figure 1). We determined a cut-off
ratio of 0.01 for absolute NPM1mut ratios and a log
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Table 3. Results of relapse analyses at different MRD checkpoints.
MRD checkpoint N. HR (95% CI)* P* Cut-off** HR Cut-off P*** Sensitivity Specificity PPV NPV P****
(95% CI)***
Aplasia
NPM1mut 49 1.43 0.068 10 2.81 0.034 29% 96% 86% 64% 0.033
ratios (0.97-2.05) (1.08-7.29) (6/21) (27/28) (6/7) (27/42)
NPM1mut 45 2.29 0.01 1 Log 4.55 0.002 39% 96% 87% 70% 0.004
kinetics (1.22-4.29) (1.73-11.97) (7/18) (26/27) (7/8) (26/37)
After induction therapy
NPM1mut 88 1.47 0.001 0.01 4.26 <0.0001 76% 74% 65% 83% <0.0001
ratios (1.17-1.84) (1.93-9.45) (26/34) (40/54) (26/40) (40/48)
NPM1mut 81 1.64 <0.0001 3 Log 5.09 <0.0001 50% 84% 65% 74% 0.002
kinetics (1.26-2.14) (2.39-10.82) (15/30) (43/51) (15/23) (43/58)
After consolidation therapy
NPM1mut 58 1.39 0.006 0.01 2.72 0.03 32% 92% 70% 69% 0.03
ratios (1.10-1.77) (1.10-6.69) (7/22) (33/36) (7/10) (33/48)
NPM1mut 48 1.34 0.016 3 Log 7.58 0.001 22% 100% 100% 68% 0.016
kinetics (1.06-1.70) (2.31-24.86) (4/18) (30/30) (4/4) (30/44)
Follow-up‡
NPM1mut 73 NA <0.0001‡ 1‡ NA NA 100% 100% 100% 100% <0.0001
ratios (7/7) (66/66) (7/7) (66/66)
HR: hazard ratio; CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value; NPM1mut: NPM1 mutation; NA: not analyzed; *Cox regression model of all NPM1mut
measurements for the occurrence of relapse; **Cut-offs determined by Cox regression models; ***Cox regression model of NPM1mut cut-off values for the occurrence of relapse; **** c2 test
of 2 × 2 contingency tables; ‡Relapse within an observation period of 100 days during follow-up; Cut-off determined by receiver-operating characteristic curve analysis.
Figure 1. NPM1mut ratios at different checkpoints in patients who achieved complete remission. Black symbols indicate NPM1mut ratios at
different checkpoints of patients who relapsed during follow-up, white symbols indicate NPM1mut ratios at different checkpoints of patients
with ongoing remission. Gray symbols indicate NPM1mut ratios of patients who subsequently underwent allogeneic stem cell transplantation
in first complete remission. Bars indicate median NPM1mut ratios at the specific checkpoint. NPM1mut: NPM1 mutation; RT - PCR: quantita-
tive real-time polymerase chain reaction; CR: NPM1 mutation ratios of patients with ongoing complete remission; Tx in CR: NPM1 mutation





























reduction of -3 log. With these cut-offs we calculated sen-
sitivities of 76% and 50% and specificities of 74% and
81% for the identification of patients at high risk of
relapse (Table 3). Both cut-off levels identified patients at
risk of relapse (HR 4.26, P<0.0001 for absolute levels, and
HR 5.09, P<0.0001 for kinetics, Table 3). The cumulative
incidence of relapse after 2 years was 77.8% for MRD
cut-off-positive patients and thus significantly higher
than that for MRD cut-off-negative patients (26.4%,
P<0.0001; Figure 2A,B). This ability to predict relapse per-
sisted in the multivariate model if added to established
risk stratification factors: age, ELN risk stratification,
white blood cell count, and lactate dehydrogenase level
(Table 4). Our cut-off level for absolute NPM1mut ratios
showed a trend to affect overall survival (Figure 2C, Table
4) and the cut-off level for kinetics separated two prog-
nostic groups in the Kaplan-Meier plot with statistically
significantly different overall survival, although the differ-
ence did not reach statistical significance in the multivari-
ate model (Figure 2D, Table 4).
NPM1 mutation ratios after consolidation therapy
After consolidation therapy 58 patients in complete
remission were available for analysis of survival data. The
absolute NPM1mut ratios and their kinetics (Table 1) had
a significant impact on relapse detection (HR of absolute
levels 1.39, P=0.006, and HR of kinetics 1.34, P=0.016,
Table 3). In accordance, patients with ongoing remission
had significantly lower NPM1mut ratios and greater log
reductions than patients with relapse during follow-up
(median NPM1mut ratio of 0.00001 versus 0.005, P=0.004
and median log reduction of -6.99 versus -4.39 log,
P=0.027, respectively; Figure 1).
Cut-off levels of NPM1mut ratio of 0.01 and of -3 log
were established and displayed low sensitivities of 32%
and 22% but high specificities of 92% and 100% (Table
3). The cut-off levels separated the cohort into two prog-
nostic groups (Online Supplementary Figure 4A,B) with haz-
ard ratios of 2.72 and 7.58. In the multivariate model with
age and ELN risk stratification, the NPM1mut ratios and
kinetics exceeding the established cut-off levels were the
only prognostic variables for cumulative incidence of
relapse and overall survival (Table 4).
NPM1 mutation ratios during follow-up
During the follow-up period, MRD was monitored in
191 bone marrow samples (including the samples after
consolidation therapy) from 81 patients in complete
remission. In accordance with previously published data
on relapse kinetics25 and as a result of individual differ-
ent MRD monitoring intervals, an evaluation period of
100 days after sampling was chosen for a prediction
analysis of relapse. Seventy-three patients in complete
remission were available for this prediction analysis.
Using ROC analysis a cut-off NPM1mut ratio of 1 was
assessed. With this cut-off all patients with an upcoming
relapse (sensitivity of 100%) within the next 100 days
could be detected prior to relapse with a median time to
relapse of 58 days (range, 20 – 98 days). None of the
patients with values below this cut-off (specificity of
100%) relapsed in the 100-day observation period
(P<0.0001, Table 3). 
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Table 4. Multivariate analyses.
Cumulative incidence of relapse Overall survival
Variable N. HR (95% CI) P N. HR (95% CI) P
In aplasia 42 32
MRD cut-off (NPM1mut ratio) 2.82 (1.08-7.31) 0.033 0.93 (0.11-7.83) 0.946
ELN (favorable vs. others) 0.83 (0.35-2.00) 0.686 0.50 (0.12-2.08) 0.340
In aplasia 38 28
MRD cut-off (Kinetics) 4.87 (1.80-13.17) 0.002 3.01 (0.48-18.95) 0.240
ELN (favorable vs. others) 0.58 (0.21-1.56) 0.279 0.29 (0.05-1.57) 0.152
After induction therapy 72 52
MRD cut-off (NPM1mut ratio) 6.16 (2.49-15.24) 0.0001 2.40 (0.84 -6.87) 0.103
ELN (favorable vs. others) 2.83 (1.19-6.75) 0.018 5.19 (1.59-16.97) 0.006
Age (per decade) 1.31 (0.91-1.88) 0.145 2.96 (1.41-6.21) 0.004
WBC (per 10 fold increase) 2.52 (1.00-6.31) 0.049 3.86 (1.34-11.10) 0.012
LDH (per one upper limit of normal) 0.94 (0.73-1.20) 0.615 NA NA
After induction therapy 66 46
MRD cut-off (Kinetics) 5.33 (2.02-14.05) 0.001 3.02 (0.89-10.30) 0.077
ELN (favorable vs. others) 1.93 (0.85-4.425) 0.118 3.23 (0.91-11.48) 0.070
Age (per decade) 1.05 ( 0.72-1.54) 0.803 2.53 (1.12-5.68) 0.025
WBC (per 10 fold increase) 2.05 (0.94-4.44) 0.07 3.96 (1.30-12.19) 0.016
After consolidation therapy 55 45
MRD cut-off (NPM1mut ratio) 2.91 (1.16-7.31) 0.023 5.06 ( 1.46-17.49) 0.010
ELN (favorable vs. others) 1.07 (0.45-2.52) 0.878 0.66 (0.19-2.32) 0.658
Age (per decade) 1.21 (0.83-1.78) 0.320 1.44 (0.81-2.58) 0.215
After Consolidation Therapy 45 30
MRD cut-off (Kinetics) 7.62 (2.25-25.88) 0.001 8.80 (1.73-44.78) 0.009
ELN (favorable vs. others) 1.04 (0.40-2.73) 0.936 0.16 (0.02-1.38) 0.164
Age (per decade) 1.20 (0.80-1.79) 0.369 NA
HR: hazard ratio; CI: confidence interval; NPM1mut: NPM1 mutation; ELN: risk stratifiation according to European LeukemiaNet;1 WBC:  white blood cell count at diagnosis; LDH:
lactate dehydrogenase level at diagnosis; NA: not analyzed.
European LeukemiaNet favorable risk group
Seventy-eight patients (51%) with normal karyotype and
no FLT3-ITD were classified as being in the ELN favorable
risk group.1 Of these, 80.8% (63 patients) achieved com-
plete remission after induction therapy and 11.5% achieved
an incomplete complete remission. Within this group with
a favorable prognosis, 45% of the patients had a relapse
during the follow-up. In patients in complete remission,
there were no differences in relapse rate, remission dura-
tion, and overall survival between the prognostically favor-
able and intermediate I (with FLT3-ITD) groups.
All estimated cut-offs for the whole cohort were con-
firmed in the ELN favorable subgroup (data not shown).
The absolute level of NPM1mut after induction therapy
seemed to be the most clinically relevant parameter. At
this checkpoint, NPM1mut ratios above the cut-off levels
defined patients with an increased risk of relapse as com-
pared to patients with MRD levels below this cut-off (HR
8.59, P=0.005). In accordance with this, the cumulative
incidence of relapse was significantly lower in the MRD
cut-off negative group (Online Supplementary Figure S6).
Stability of NPM1 mutations at relapse
MRD could be assessed at relapse in 45 patients with a
median NPM1mut ratio of 58.8 (range, 0.000001 – 326.0).
The NPM1mut ratios at relapse did not differ from those
at diagnosis (P=0.25). In three out of the 45 patients
(6.7%) no NPM1mut signal could be detected by RT-PCR.
One of these patients also lost FLT3-ITD at relapse after
37.6 months and gained a chromosomal aberration t(1;7).
In this patient, a DNMT3A mutation present at diagnosis
was also detected in the relapse sample. The second
patient relapsed after HSCT and lost the initial leukemia-
associated immunophenotype at relapse. The third
patient relapsed after 5.6 months and gained a JAK2
mutation at relapse (Online Supplementary Table S2).
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Figure 2. Cumulative incidence of relapse (A and B) and overall survival (C and D) after induction therapy according to MRD status of
NPM1mut ratios and NPM1mut kinetics. (A) and (C) NPM1mut ratios after induction therapy with a NPM1mut cut-off ratio of 0.01; (B) and
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Impact of consolidation therapy on the course 
of minimal residual disease 
We analyzed the impact of consolidation therapy on the
course of MRD in individual patients in complete remis-
sion after induction and consolidation therapy. Forty-four
patients had paired MRD samples at both checkpoints
before and after consolidation therapy (Figure 3).
Nineteen patients showed MRD levels above the esti-
mated cut-off after induction therapy. Six out of these 19
patients stayed MRD-positive (according to the estimated
NPM1mut ratio cut-off) after the end of consolidation
therapy and five patients relapsed after a median of 4
months (range, 1 – 11 months). The remaining double
MRD-positive patient had weakly positive MRD levels at
both checkpoints (0.07 and 0.03, respectively) and
became RT-PCR negative throughout the maintenance
therapy. In 13 patients MRD levels decreased below the
estimated cut-off after consolidation therapy.
Nevertheless, nine of these patients relapsed, while four
remained in complete remission. Three of these four
patients underwent HSCT in first complete remission .
Twenty-five patients were MRD cut-off negative after
induction therapy and 24 patients stayed MRD cut-off
negative after consolidation therapy. Six patients were
transplanted in first complete remission and in 14 double
MRD cut-off negative patients no relapse occurred after a
median follow-up of 26 months (range, 1-105 months).
Four double MRD cut-off-negative patients relapsed after
a median of 15 months (range, 5-32 months). In one of
these patients, MRD sampling 90 days prior to relapse
was possible and resulted in a NPM1mut ratio of 8.6,
clearly above the follow-up cut-off ratio of 1. 
Only one patient was initially MRD cut-off-negative
after the induction therapy and showed weakly positive
MRD levels after the consolidation therapy (NPM1mut
ratio 0.02). The further follow-up sample was RT-PCR-
negative and the patient is still in remission after 21
months.
In this analysis of paired samples, MRD status after
consolidation therapy in comparison to the MRD status
after induction therapy has changed in 14 patients (32%),
and in only four patients (29%) did this change in MRD
indicate the correct outcome.
Discussion
In this study, we assessed MRD at different check-
points throughout conventional chemotherapy in 158
AML patients with NPM1 mutations. All patients
received intensive, high-dose cytarabine induction thera-
py within one of three AMLCG trials. Major goals of this
study were: (i) to identify relevant assessment check-
points for MRD and (ii) to establish cut-off levels for the
prediction of relapse. 
The NPM1mut ratio at diagnosis did not show any
impact on survival, or on relapse occurrence. After induc-
tion therapy seemed to be the most appropriate check-
point to assess MRD levels in order to identify patients in
complete remission at high risk of relapse. The cut-off
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Figure 3. MRD assessment after induction and consolidation therapy in patients with paired samples. In total, 18 patients relapsed after con-
solidation therapy with a median time to relapse of 9.9 months. Nine patients were transplanted in first complete remission with a median
time to allogeneic stem cell transplantation of 1.2 months and 17 patients had an ongoing remission with a median follow-up of 31.1 months
after consolidation therapy. NPM1mut: NPM1 mutation; FU: follow-up period; CR: first complete remission; Tx: allogeneic stem cell transplan-
tation in first complete remission.
values of the NPM1mut ratios and the kinetics of these
ratios after induction therapy had high hazard ratios in
multivariable analysis and yielded high sensitivity and
specificity values. Interestingly, the same cut-off levels
after consolidation therapy had less impact on cumulative
incidence of relapse than the MRD cut-off after induction
therapy. In addition, consolidation therapy showed no
clear MRD reduction in MRD cut-off-positive patients
after induction therapy. Hence, in this biological sub-
group with its slow relapse kinetics,25 a quick and deeper
molecular response after induction therapy seems to be
more prognostically relevant than persistent MRD posi-
tivity after consolidation therapy. Thus, we conclude that
MRD levels after induction therapy should be used to
identify patients at high risk of relapse. 
Krönke et al.,10 and Shayegi et al.11 analyzed clinically
relevant MRD checkpoints in NPM1-mutated patients.
They, too, identified MRD assessment after induction
therapy, or after the achievement of complete remission,
as one of the most important MRD checkpoints. They
demonstrated that positive MRD levels at this check-
point identify patients at high risk of relapse and shorter
overall suvival. In contrast to Krönke et al. and in accor-
dance with Shayegi et al. we found that a low level of
MRD (cut-off ratio of 0.01) after induction therapy is
superior to RT-PCR negativity for identifying patients at
high risk of relapse (see Online Supplementary Material).
During the follow-up period, our estimated cut-off ratio
of 1 identified all relapses within the next 100 days after
sampling and all patients with lower NPM1mut ratios
stayed in remission for the next 100 days. While our
analysis confirmed the significant impact of MRD posi-
tivity on cumulative incidence of relapse, we observed
only a trend for overall survival (Figure 2). This might be
the consequence of a smaller cohort of patients, study
design, the censored survival data at HSCT, or a short
follow-up after relapse.
The monitoring and interpretation of NPM1mut MRD
assessments are still restricted to centralized laboratories.
As a result of different RT-PCR assays, conditions, treat-
ment protocols and clinical situations, it is very difficult to
compare the estimated cut-offs at the different MRD
checkpoints. Shayegi et al. established clinical cut-offs by
ROC analyses and Cox regression models. After the
achievement of complete remission they estimated a cut-
off level of 1% and after HSCT a higher cut-off level  of
10%.11 We focused our MRD analyses on patients after
conventional chemotherapy and identified an NPM1mut
ratio of 0.01 as the best cut-off value after induction ther-
apy and a cut-off ratio of 1 during the follow-up period.
Only the MRD log reduction can be compared through-
out the different MRD studies. Consistent with our data,
Schnittger et al.17 also found that a 3-log reduction identi-
fed patients at high risk of relapse. Joint efforts such as
the standardization of Wilms’ tumor 1 (WT1) gene
expression9 or BCR-ABL5 are needed. Until there is har-
monization of NPM1mut RT-PCR assays, enabling subse-
quent interlaboratory comparison, centralized MRD
assessment and interpretation at one laboratory of each
study group is obligatory.
The ELN has published a risk stratification considering
cytogenetics and molecular genetic analyses at diagno-
sis.1,3 The ELN favorable risk group of our study cohort is
the most clinically interesting subgroup. In contrast to the
intermediate I group (with an additional FLT3-ITD)
HSCT is usually not recommended in these patients.26
However, in our cohort of patients, 45% of the NPM1mut
patients without FLT3-ITD relapsed and we found no sig-
nificant differences in relapse rate, remission duration,
and overall survival between the ELN favorable and inter-
mediate I groups. This might be because of the heteroge-
neous age of patients within the AMLCG trials, which
had no age restrictions. Depending on the quantity of
FLT3-ITD mRNA,27 FLT3-ITD might have a prognostic
impact in NPM1mut AML and require a more individual-
ized treatment. In other hematologic malignancies, such
as acute lymphoblastic leukemia and chronic myeloid
leukemia, MRD-guided therapies are already established.
Pre-emptive therapy based on MRD monitoring in
patients with acute promyelocytic leukemia improved
the outcome of patients in the MRC AML15 trial, in a his-
torical comparison to previous trials.7 However, only a
few prospective studies with MRD-guided therapies are
available in non-acute promyelocytic forms of AML.28-30
Our results and those of others demonstrate the feasi-
bility and reliability of serial NPM1mut MRD monitoring
to identify patients at high risk of relapse.10,11,19 Since
HSCT in NPM1mut patients does not impair the relapse-
free survival26 and, as shown in our analyses, MRD cut-
off-positive patients are at high risk of relapse, these
patients should be considered for more intensified post-
remission therapy, to improve the relapse rate and overall
survival, and should undergo HSCT, if eligible. 
Instability of MRD markers is a potential problem of
MRD-guided therapy and FLT3-ITD can be unstable dur-
ing follow-up.31,32 The stability of NPM1mut has been
debated. In the relapse samples analyzed by Schnittger et
al.17 all relapsed patients showed the initial NPM1mut at
relapse. This is in contrast to our results and those of
Krönke et al.,10 with mutated NPM1 being undetectable at
relapse in 6.7% and 9% of patients, respectively. In our
analyses, one of the three relapsed patients with unde-
tectable NPM1mut at relapse did relapse after more than
2 years with different chromosomal aberrations and a dif-
ferent leukemia-associated immunophenotype, but with
a stable DNMT3A mutation.33 The other two patients
relapsed within 6 months after achieving complete remis-
sion. One patient also showed the initial leukemia-associ-
ated immunophenotype with an additional JAK2 muta-
tion at relapse (Online Supplementary Table S2). Thus, in
these patients a clonal evolution or a relapse of a subclone
of the initial leukemia is very likely. Considering this
aspect, monitoring a second, stable molecular marker, e.g.
DNMT3A,33 or monitoring MRD by an alternative
method, e.g. flow cytometry, may improve the relapse
prediction rate and lower the rate of false negative MRD
results.
In conclusion, our results showed the prognostic impact
of NPM1MRD monitoring by RT-PCR. MRD monitoring
can identify patients at high risk of relapse, especially in
the clinically relevant subgroup of the ELN favorable-risk
patients. Particularly high MRD levels above our estimat-
ed cut-off after induction therapy were strongly associat-
ed with a high cumulative incidence of relapse. This and
data previously published by others demonstrate that, in
addition to pre-therapeutic prognostic factors, the indi-
vidual course of MRD should be used as new prognostic
factor for the guidance of treatment and patients with
high or increasing levels of MRD should undergo HSCT,
if eligible. 
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